Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

RIXACAM 15 MG CÁPSULAS DURAS EFG - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/RIXACAM 15 MG CÁPSULAS DURAS EFG

Approved

STANDARD

RIXACAM 15 MG CÁPSULAS DURAS EFG

Adamed Laboratorios S.L.U.🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Feb 5, 2024
Approval ID: 259dd21bbb29d650
Company: Adamed Laboratorios S.L.U.
Type: Standard

Approval Details

Approval Id: 259dd21bbb29d650
Drug Cima Aemps Name: RIXACAM 15 MG CÁPSULAS DURAS EFG
Register Number: 89077
Holder Company Name: Adamed Laboratorios S.L.U.
Marketing Company Name: Adamed Laboratorios S.L.U.
Authorization Date: 2024-02-05
Dosage Form: CÁPSULA DURA
Dose: 15
Route Of Administration: VÍA ORAL
Prescription Type: Medicamento Sujeto A Prescripción Médica
Commercialized: No
Company Name: Adamed Laboratorios S.L.U.

Active Ingredients

RIVAROXABAN

15 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Feb 5, 2024

Approval ID

259dd21bbb29d650

Type

Standard

Back to CIMA-AEMPS Approvals